Related Experiment Videos
Triamcinolone versus inner-limiting membrane peeling in persistent diabetic macular edema (TIME study): design issues
Antonia M Joussen1, Claudia Weiss, Diana Bauer
1Department of Ophthalmology, University Hospital Duesseldorf, University of Duesseldorf, Moorenstrasse 5, 40225 Duesseldorf, Germany. joussena@googlemail.com
Summary
The TIME study compares intravitreal triamcinolone injections and internal limiting membrane (ILM) peeling for persistent diabetic macular edema. Results will guide physicians in choosing the most effective treatment for individual patients.
Area of Science:
- Ophthalmology
- Retinal diseases
- Diabetic retinopathy
Background:
- Persistent diabetic macular edema (DME) presents limited treatment options.
- Intravitreal triamcinolone and ILM peeling are used for DME, but comparative efficacy is unknown.
Purpose of the Study:
- To investigate the efficacy of intravitreal triamcinolone versus ILM peeling in patients with persistent DME.
- To compare these treatments against a control group.
Main Methods:
- The TIME study is a randomized clinical trial involving 135 patients per group.
- Treatments include no treatment, pars plana vitrectomy with ILM peeling, or triamcinolone injection.
- Primary endpoints are visual acuity change at 12 months and retinal thickness change at 3 months.
Main Results:
- The design and implications of the TIME study are detailed.
- This section will present the comparative effectiveness of the interventions.
Conclusions:
- The TIME study is the first randomized trial comparing these DME treatments.
- Results aim to optimize therapy selection for persistent diabetic macular edema.